Improvements in adherence were not consistently translated into observable benefit for clinical outcomes in our pooled analyses. None of the intervention types showed clear benefit for our primary clinical outcomes - exacerbations requiring an oral corticosteroid (OCS) (evidence of very low to low quality) and asthma control (evidence of low to moderate quality); nor for our secondary outcomes - unscheduled visits (evidence of very low to moderate quality) and quality of life (evidence of low to moderate quality). However, some individual studies reported observed benefits for OCS and use of healthcare services. Most school or work absence data were skewed and were difficult to interpret (evidence of low quality, when graded), and most studies did not specifically measure or report adverse events.
According to the International Programme on Chemical Safety (IPCS) and United States Food and Drug Administration (USFDA), [note 7] amphetamine is contraindicated in people with a history of drug abuse , [note 8] cardiovascular disease , severe agitation , or severe anxiety.    It is also contraindicated in people currently experiencing advanced arteriosclerosis (hardening of the arteries), glaucoma (increased eye pressure), hyperthyroidism (excessive production of thyroid hormone), or moderate to severe hypertension .    People who have experienced allergic reactions to other stimulants in the past or who are taking monoamine oxidase inhibitors (MAOIs) are advised not to take amphetamine,    although safe concurrent use of amphetamine and monoamine oxidase inhibitors has been documented.   These agencies also state that anyone with anorexia nervosa , bipolar disorder , depression, hypertension, liver or kidney problems, mania , psychosis , Raynaud's phenomenon , seizures , thyroid problems, tics , or Tourette syndrome should monitor their symptoms while taking amphetamine.   Evidence from human studies indicates that therapeutic amphetamine use does not cause developmental abnormalities in the fetus or newborns (., it is not a human teratogen ), but amphetamine abuse does pose risks to the fetus.  Amphetamine has also been shown to pass into breast milk, so the IPCS and USFDA advise mothers to avoid breastfeeding when using it.   Due to the potential for reversible growth impairments, [note 9] the USFDA advises monitoring the height and weight of children and adolescents prescribed an amphetamine pharmaceutical.